Antidepressant Discontinuation Syndrome: Symptoms, Duration, and How to Taper Safely
Author:
Blossom Editorial
Jun 2, 2026
When people stop taking antidepressants, especially SSRIs and SNRIs, they may experience distressing physical and emotional symptoms in the days or weeks that follow. This is called antidepressant discontinuation syndrome (ADS), and it is more common than many people realize.
Discontinuation syndrome is not a sign of addiction or personal weakness. It is a physical adjustment process that occurs when the brain has adapted to a steady level of medication and then suddenly has less of it.
Understanding why it happens, what symptoms to expect, and how to stop antidepressants safely can help reduce distress and confusion during the process.
Key Takeaways
ADS can occur when selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) are stopped abruptly, and are reported in about 20-40% of people. Symptoms often begin within 1–4 days of stopping the medication and for many people, they typically resolve within 2–4 weeks. But others may experience symptoms for longer.
Common symptoms include dizziness, flu-like sensations, nausea, irritability, sleep disruption, and "brain zaps", which are brief electric shock-like sensations in the head.
Gradually tapering antidepressants under medical supervision can help reduce the risk of discontinuation symptoms.
What Is Antidepressant Discontinuation Syndrome (ADS)?
ADS refers to a group of symptoms that can occur after stopping or rapidly reducing certain antidepressants.
It was first widely recognized in the 1990s from a landmark review published in the Journal of Clinical Psychiatry. SSRIs became more widely prescribed, and clinicians began noticing consistent patterns in people who stopped treatment abruptly. Since then, it has been included in the treatment guidelines and the prescribing information of many SSRIs and SNRIs.
The syndrome occurs because SSRIs and SNRIs can gradually alter the brain's serotonin signaling over time. As the brain adapts to the medication, changes occur in receptor sensitivity and neurotransmitter activity.
When the medication is stopped suddenly, the brain may not immediately readjust, resulting in a temporary neurochemical imbalance and ADS.
Many clinical studies suggest that ADS is not considered addiction in the clinical sense. This is because it doesn’t usually involve craving, drug-seeking behavior, or escalating tolerance.
Instead, the experience is more similar to what can happen when someone abruptly stops other medications that the body adjusts to over time. These medications include beta-blockers or corticosteroids, where the body gradually adjusts, and symptoms typically emerge during that adjustment.
Which Antidepressants Are More Likely to Cause Discontinuation Syndrome?
The risk of ADS can vary significantly depending on a medication's half-life.
Half-life is the time it takes for the body to eliminate half the drug. Medications with shorter half-lives leave the body more quickly, creating a more abrupt neurochemical change. And medications with longer half-lives typically allow a more gradual transition.
Higher-Risk Medications
According to the FDA prescribing information for Paxil (Paroxetine), it is associated with some of the highest rates of discontinuation symptoms among SSRIs. This is because it has a relatively shorter half-life.
Effexor XR (Venlafaxine) is also strongly associated with discontinuation symptoms of SSRIs. It is often considered one of the more difficult antidepressants to stop abruptly.
Moderate-Risk Medications
Medications with a moderate risk of ADS include:
Zoloft (sertaline)
Lexapro (escitalopram)
Cymbalta (duloxetine)
Pristiq (desvenlafaxine)
Lower-Risk Medications
Prozac (fluoxetine) is generally associated with a lower risk of discontinuation symptoms because it leaves the body very slowly. Its long half-life helps create a gradual self-taper, which may reduce the likelihood of ADS.
Antidepressant Discontinuation Symptoms
The symptoms of antidepressants are distinct and often follow a recognizable pattern. Clinicians commonly use the ‘FINISH’ mnemonic to group the main symptoms, which usually appear together rather than on their own.
The FINISH Mnemonic for Discontinuation Symptoms
Each letter represents a group of symptoms that can help health care providers and people with ADS recognize and communicate about the syndrome.
F — Flu-like symptoms: These may include fatigue, muscle aches, chills, and sweating without fever or illness
I — Insomnia: This may include disrupted sleep, frequent waking, vivid or disturbing dreams, and nightmares
N — Nausea: Digestive symptoms may include vomiting, nausea, and stomach discomfort
I — Imbalance: People often report dizziness, vertigo, lightheadedness, and feeling unsteady while walking
S — Sensory disturbances: These may include tingling sensations in hands or feet, burning sensations, and ‘brain zaps.’
H — Hyperarousal: This may include anxiety, irritability, agitation, emotional sensitivity, and mood swings
Brain Zaps: What Are They?
Brain zaps are one of the most distinctive and sometimes alarming symptoms of ADS. They are brief and sudden sensations often described as electric shocks or "zaps" in the head and may radiate outward.
Although brain zaps are not generally painful for many people, they can feel deeply unsettling. Especially when people who experience them don’t understand what is causing them. Some people report that they are often triggered by rapid eye or sudden head movement. They are strongly associated with changes in serotonin levels and are typically recognized as a hallmark symptom of SSRI and SNRI discontinuation. Brain zaps usually improve as the brain gradually readjusts to the medication.
How Long Does Antidepressant Withdrawal Last?
For many people who stop SSRIs abruptly, discontinuation symptoms often begin within 1–4 days, peak around days 5–10, and usually resolve within 2–4 weeks. However, the timeline may not be the same for everyone.
A 2019 review by Fava and colleagues reported that some people may experience symptoms that can last for months in some cases. This usually happens after long-term treatment or after stopping medications such as paroxetine or venlafaxine.
Several factors can influence symptom severity and duration, including:
The specific antidepressant
Dose and duration of treatment
How quickly the medication was tapered
Individual sensitivity to medication changes
Research also suggests that slower, more gradual tapers may reduce the risk of prolonged or severe symptoms.
Discontinuation Syndrome vs. Relapse: How to Tell the Difference
One of the biggest clinical challenges after stopping antidepressants is differentiating between ADS and symptoms from the relapse of the depression or anxiety. This distinction matters because the two situations require different responses.
Discontinuation Syndrome Often:
Begins within days of stopping medication
Includes physical symptoms such as brain zaps, dizziness, flu-like sensations, or tingling sensations
Gradually improves over time (typically 2-4 weeks)
Relapse Often:
Begins more gradually over weeks or months
Includes emotional symptoms such as low mood, hopelessness, anxiety, or difficulty functioning
Continues or worsens without treatment rather than improving over time
The two experiences can still overlap. If symptoms appear after reducing or stopping medication, it’s important to discuss them with a healthcare provider.
How to Stop Antidepressants Safely
One important principle is to avoid stopping antidepressants abruptly without medical guidance. Your healthcare provider can help determine whether stopping is clinically appropriate, design a taper that fits your medication and history, and monitor for both discontinuation symptoms and relapse.
Gradual Tapering
The standard clinical approach typically involves reducing the dose gradually over weeks or months.
Some researchers, including Horowitz and Taylor in The Lancet Psychiatry, have also suggested the potential benefits of hyperbolic tapering. It involves dose reductions that become progressively smaller at lower doses.
Many people usually experience the most noticeable symptoms during the later stages of tapering. Therefore, slower reduction at lower doses may be helpful in reducing discontinuation symptoms.
Switching to a Longer Half-Life Medication
For people taking higher-risk medications such as paroxetine or venlafaxine, healthcare providers may suggest switching to fluoxetine first.
Because fluoxetine leaves the body more slowly, its gradual self-elimination may help create a smoother adjustment process and reduce the abruptness of neurochemical changes. S
Seeking Help for Discontinuation Symptoms
Stopping antidepressants can feel overwhelming, especially if unexpected symptoms appear along the way. But with the right tapering plan and medical support, many people can reduce or stop their medication safely and more comfortably over time.
If you're experiencing discontinuation symptoms or thinking about changing or stopping your antidepressant treatment, our board-certified psychiatric providers at Blossom Health can help you create a personalized plan that fits your symptoms, treatment history, and goals. Book your appointment now to get convenient virtual care covered by insurance.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. The information provided should not replace consultation with a qualified healthcare provider. Individual responses to medications can vary significantly, and what applies to one person may not be the same for another.
Always consult with your doctor or pharmacist before making any decisions about medication changes, discontinuation, or interactions with other substances. If you’re experiencing concerning symptoms or side effects, please seek professional help from a healthcare provider.
In case of a medical emergency, contact your local emergency services immediately or call 911. For mental health emergencies, contact the National Suicide Prevention Lifeline at 988.
Sources
Schatzberg, A. F., Haddad, P., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997). Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. The Journal of clinical psychiatry, 58 Suppl 7, 5–10. https://pubmed.ncbi.nlm.nih.gov/9219487/
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015). Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychotherapy and psychosomatics, 84(2), 72–81. https://doi.org/10.1159/000370338
Warner, C. H., Bobo, W., Warner, C., Reid, S., & Rachal, J. (2006). Antidepressant discontinuation syndrome. American family physician, 74(3), 449–456. https://pubmed.ncbi.nlm.nih.gov/16913164/
Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The lancet. Psychiatry, 6(6), 538–546. https://doi.org/10.1016/S2215-0366(19)30032-X
FDA. (October, 2023) Lexapro (escitalopram) prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf
FDA. (February, 2021). Paxil (paroxetine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020031s077lbl.p
FDA. (January, 2017) Effexor VR (venlafaxine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.p
Gabriel, M., & Sharma, V. (2017). Antidepressant discontinuation syndrome. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 189(21), E747. https://doi.org/10.1503/cmaj.160991
National Institute of Mental Health. (December, 2023). Mental Health Medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
Cleveland Clinic. (August 29, 2025). Antidepressants.https://my.clevelandclinic.org/health/treatments/9301-antidepressants-depression-medication
American Psychiatric Association. (October, 2010). Practice guidelines for major depressive disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
